Below is a partial list of conference topics and speakers:

Monday, September 27

8:15 a.m.          Welcoming and Introductions (Ambassador Ballroom – Level 3)

8:45 a.m.          Plenary Presentation:
                           Progress in Translating Drug Abuse Research into Clinical Practice
                           Nora D. Volkow, M.D., Director
                           National Institute on Drug Abuse/NIH
                           Ambassador Ballroom – Level 3

10:00 a.m.       Break

10:15 a.m.       Presentation:
                          Disease Management: Addiction as a Chronic Relapsing Disease
                          Thomas Carli, M.D., Medical Director
                          Medical Management Center and Disease Management Programs at the University of Michigan Health System
                          Ambassador Ballroom – Level 3

11:45 a.m.      Poster Session (Ontario West Exhibit Hall - Level 3)

12:30 p.m.      Lunch (Ambassador Ballroom - Level 3)

2:30 p.m.        Workshops 1-6
                         1.  Methamphetamine: Epidemiology, Neurotoxicity, and Treatment
                              Charles R. Schuster, Ph.D., Chris-Ellyn Johanson, Ph.D., Patricia Marinelli-Casey, Ph.D., Anna Talamo, M.A., M.F.T.
                              Cartier - Level 4

                         2.  Motivational Interviewing: What It Is, How It Works, and How to Make It Work in Your Agency
                              William R. Miller, Ph.D., Steve Ondersma, Ph.D., LP, Ned Snead, M.S.
                              Cabot - Level 4

                         3.  Buprenorphine: From Basic Human Research to Clinical Application
                              Mark Greenwald, Ph.D., Walter Ling, M.D., Virginia S. Ryan, Ph.D., Allan Cohen, M.D., M.F.T.
                              LaSalle B - Level 5

                         4.  Transitions Across Stages and Levels of Drug Involvement
                              James Anthony, Ph.D., Richard Spoth, Ph.D., Tom Dishion, Ph.D., Ty Ridenour, Ph.D., M.P.E.
                              Richard A - Level 5

                        5.  Treatment on Demand: How It Has Affected the Cities of Detroit, San Fransisco, Philadelphia, and Baltimore
                             Yvonne Anthony, Ph.D., Calvin Trent, Ph.D., Joseph Guydish, Ph.D., Melisa Lindamood, MPS, Mark Bencivengo, M.A.
                             LaSalle A - Level 5

                        6.  Addressing Medical and Psychiatric Needs in Substance Abuse Treatment
                             Michael Liepman, M.D., Jeff Selzer, M.D., John Hopper, M.D., Kathleen Sheenan, RN, Anne Benion, A.C.S.W.
                             Richard B - Level 5

5:00 p.m.       Adjourn Day One

Tuesday, September 28

8:30 a.m.          Panel Discussion:
                           Issues of Race and Ethnicity in Substance Abuse Treatment
                           José Szapocznik, Ph.D., Daniel Santisteban, Ph.D., Dale Walker, M.D.,
                           Lawrence Brown, M.D., MPH, FASAM
                           (Ambassador Ballroom - Level 3)

9:45 a.m.         Break

10:00 a.m.      Workshops 7-12
                         7. Behavioral Therapies in Substance Abuse Treatment: Contingency Management & Cognitive Behavioral Therapy
                              Kathleen Carroll, Ph.D., Maxine Stitzer, Ph.D., and Gary Rhodes, M.A.
                              Ambassador 1 - Level 3

                         8.  Co-occurring Disorders in Substance Abuse Treatment
                              Kathleen Brady, M.D., Bruce Rounsaville, M.D., Eric Schindler, Ph.D.
                              Cabot - Level 4

                        9.  Women and Co-morbidity
                             Cynthia Arfken, Ph.D., Sheryl Pimlott Kubiak, Shelly Greenfield, M.D., M.P.H., Susan Gordon, Ph.D., Gloria Miele, Ph.D.
                             Cartier - Level 4

                       10. Treatment Interventions to Prevent the Next Generation of Substance Abusers: Family Based Approaches
                              Robert Zucker, Ph.D., Deborah Ellis, Ph.D., Karol Kumpfer, Ph.D.
                              LaSalle A and B - Level 5

                       11. Evidence-Based Practice: What it means to the Provider
                              Lonnetta Albright, Joe Rosenfeld, Ph.D., Steve Gallon, Ph.D., Gregory Brigham, Ph.D.
                              Richard A and B - Level 5

                       12. Adjusting Intensity of Substance Abuse Treatment to Patient Need
                             Robert Brooner, Ph.D., Ron Jackson, M.S.W., James McKay, Ph.D.
                             Mackinac West - Level 5

12:30 p.m.    Lunch and The Eileen Pencer Lecture (Ambassador Ballroom - Level 3)
                       Lawrence Brown, Jr., M.D., M.P.H.

2:00 p.m.      Blending Conference Adjourns

2:00 p.m.      Mini-Courses

                       1. An Introduction to Motivational Interviewing
                           Steve Ondersma, Ph.D.
                           LaSalle A – Level 5

                       2. Buprenorphine for the Treatment Team
                           Susan Stine, M.D., Ph.D., Laura F. McNicholas, M.D., Ph.D., Albert Hasson, MSW
                           LaSalle B – Level 5

                       3. Issues Related to HIV and Hepatitis C in Substance Abuse
                           John Hopper, M.D., Jeffery Samet, M.D., M.A., M.P.H.
                           Richard A – Level 5

                      4. Best Practice in Addiction Treatment: How to Improve Skills as a Consumer of Research
                           Lonetta Albright, Steve Gallon, Ph.D., Joe Rosenfeld, Psy.D., Ph.D., Wendy Hausotter, M.P.H.
                           Richard B – Level 5

5:00 p.m.     Adjourn Day Two

Who Should Attend  |  Conference Topics  |  Logistics   |  Registration  |  Conference Partners  |  Continuing Education  |  Home